- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Short-term glucocorticoids decrease insulin secretion in type 2 diabetes
Última actualización 15 de agosto de 2026
Key finding
The increase in AUC Glucose was significantly higher (p = 0.016) in the T2DM group.
This study examined the effects of short-term high-dose glucocorticoid exposure on beta-cell function in adults with type 2 diabetes, finding significant changes in glucose and insulin metrics.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study examined the effects of short-term high-dose glucocorticoid exposure on beta-cell function in adults with type 2 diabetes, finding significant changes in glucose and insulin metrics.
Clinical relevance
Understanding the impact of glucocorticoids on beta-cell function is crucial for managing diabetes treatment. These findings highlight the need for careful consideration of glucocorticoid use in patients with type 2 diabetes, as it may exacerbate insulin resistance and hyperglycemia.
Keep in mind
Non-randomized study design may introduce bias. Limited sample size affects generalizability. Short duration of glucocorticoid exposure may not reflect long-term effects.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Monica S, May MA, Bettina T, Yannis G, Leon F, Zhiming Z. Impact of short-term high-dose glucocorticoid exposure on beta-cell function in type 2 diabetes. PLOS ONE. 2020;15(5):e0231190. doi:10.1371/journal.pone.0231190
Efectos Principales
AUC glucose increased significantly in the T2DM group (p = 0.016).
C-peptide AUC decreased significantly in the T2DM group.
Insulinogenic index decreased significantly in the T2DM group (69.2% vs 34.3%, p = 0.008).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Prednisone 40 mg daily for 3 days and C-peptide, Change in insulinogenic index from baseline to week 12, Glucose area under the curve (AUC), and 3 more.
This study contributes evidence to
Primary intervention
Prednisone 40 mg daily for 3 days
Primary outcomes
- C-peptide
- Change in insulinogenic index from baseline to week 12
- Glucose area under the curve (AUC)
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
6
Evidence pairs
316
Related studies
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 1 direct semantic evidence topic
Topic contributions
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
Glycemic Control
matched_outcome
Core evidence
Study findings
The primary outcomes reported in this study.
Change in insulinogenic index from baseline to week 12
Prednisone 40 mg daily for 3 days → Change in insulinogenic index from baseline to week 12
Prednisone 40 mg daily for 3 days → Change in insulinogenic index from baseline to week 12
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 25
- Negative
- ConsistencyScore™
- unclear
- Not enough independent studies
Glucose area under the curve (AUC)
Prednisone 40 mg daily for 3 days → Glucose area under the curve (AUC)
Prednisone 40 mg daily for 3 days → Glucose area under the curve (AUC)
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 25
- Negative
- ConsistencyScore™
- unclear
- Not enough independent studies
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Insulin resistance
Prednisone 40 mg daily for 3 days → Insulin resistance
Prednisone 40 mg daily for 3 days → Insulin resistance
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Postprandial insulin AUC
Prednisone 40 mg daily for 3 days → Postprandial insulin AUC
Prednisone 40 mg daily for 3 days → Postprandial insulin AUC
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- AUC glucose increased by 117.3 mmol/L/min in the T2DM group (p = 0.016).
- C-peptide AUC decreased by 49.4 nmol/L/min.
- Insulinogenic index decreased by 42.2% (p = 0.008).
A quién se aplica
- Adults diagnosed with type 2 diabetes.
- Patients undergoing treatment that includes glucocorticoids.
Tener en Cuenta
- Results may not be applicable to all populations with diabetes.
- Further research is needed to confirm long-term effects.
- The study's findings are based on a small sample size.
Entre Líneas
- Non-randomized study design may introduce bias.
- Limited sample size affects generalizability.
- Short duration of glucocorticoid exposure may not reflect long-term effects.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Prednisone 40 mg daily for 3 days and C-peptide, Prednisone 40 mg daily for 3 days and Postprandial and OGTT Glucose.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 25
- Negative
- ConsistencyScore™
- unclear
- Not enough independent studies
Incluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
C-peptide Evidence Hub
All studies measuring C-peptide
Measures C-peptide as a key outcome.
Postprandial and OGTT Glucose Evidence Hub
All studies measuring Postprandial and OGTT Glucose
Measures Postprandial and OGTT Glucose as a key outcome.
Prednisone 40 mg daily for 3 days Evidence Hub
All studies on Prednisone 40 mg daily for 3 days
Contributes to Prednisone 40 mg daily for 3 days evidence base.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Prednisone 40 mg daily for 3 days and C-peptide
1 results
All studies on Prednisone 40 mg daily for 3 days and Glucose area under the curve (AUC)
1 results
All studies on Prednisone 40 mg daily for 3 days
1 results
All studies measuring C-peptide
1 results
All studies measuring Glucose area under the curve (AUC)
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Prednisone 40 mg daily for 3 days improve c-peptide?
Current evidence does not show a clear benefit of Prednisone 40 mg daily for 3 days for C-peptide.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
C-peptide
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Prednisone 40 mg daily for 3 days improve homa-b?
Current evidence does not show a clear benefit of Prednisone 40 mg daily for 3 days for HOMA-B.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HOMA-B
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Prednisone 40 mg daily for 3 days improve insulin resistance?
Current evidence does not show a clear benefit of Prednisone 40 mg daily for 3 days for Insulin resistance.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Insulin resistance
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Prednisone 40 mg daily for 3 days improve postprandial insulin auc?
Current evidence does not show a clear benefit of Prednisone 40 mg daily for 3 days for Postprandial insulin AUC.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Postprandial insulin AUC
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.
